GCC And UAE Diabetes Devices Market To Reach $4.73 Billion By 2030

GCC And UAE Diabetes Devices Market Growth & Trends

The GCC and UAE diabetes devices market size is estimated to reach USD 4.73 billion by 2030, registering to grow at a CAGR of 7.3% from 2025 to 2030 according to a new report by Grand View Research, Inc. Factors such as the increasing prevalence of diabetes, rapid technological advancements, and increasing awareness related to diabetes preventive care are all augmenting the market growth during the forecast period. For instance, in December 2021, Sanofi signed a contract with the Dasman Diabetes Institute and Research Center (DDI), a research institute & diabetes treatment center in Kuwait, to enhance diabetes control and prevention in the country.

Diabetes is a rapidly growing disease. Some of the highest diabetes prevalence rates in the world are found in the countries of the Gulf Cooperation Council. The increase in unhealthy living continues to lead to a more unhealthy population in the region. According to International Diabetes Federation, in 2021, there were about 0.8 million patients suffering from diabetes in Kuwait, and this number is expected to increase to 1.0 million by 2045.

Over the past few decades, diabetes-related research activity has been observed to be low in this region. However, an increase in research funding and collaborations between local & international researchers and institutes are expected to boost segment growth. For instance, in January 2022, the Saudi Health Council signed a memorandum of understanding with Sanofi, a French healthcare corporation, to collaborate on diabetes research and development.

The key market players are implementing a variety of strategies, including mergers and acquisitions, partnerships, collaborations, and expansions. For instance, in August 2022, Abbott partnered with WW International, Inc. (WeightWatchers). Through this partnership, both companies will combine the weight management program of WeightWatchers for people with diabetes with Abbott's line of FreeStyle Libre products to produce a seamless mobile experience. It will offer knowledge & insights on how to improve their diet, lower the blood sugar levels of patients, and ultimately, help consumers take back control of their health.

 Request a free sample copy or view report summary: GCC And UAE Diabetes Devices Market Report

GCC And UAE Diabetes Devices Market Report Highlights

• The pharmaceutical, drugs, and supplies segment led the market and accounted for the largest market share of 39.5% in 2024.  

• The hospital pharmacies segment held the dominant position in the market with the highest revenue share of 55.3% in 2024.

• The hospital segment dominated the GCC and UAE diabetes devices industry and accounted for the largest revenue share of 42.4% in 2024.

GCC And UAE Diabetes Devices Market Segmentation

Grand View Research has segmented the GCC And UAE diabetes devices market based on services, distribution channel, end-use, and country:

GCC And UAE Diabetes Devices Services Outlook (Revenue, USD Million, 2018 - 2030)

• Devices and Wearables

• Pharma, Drugs and Supplies

• Technology Platforms and products

• Genomics and Multi omics

• Diabetes Prevention

  • Prediabetes Early Intervention

  • Early Diagnosis and Diabetes

  • Behavioral and Lifestyle Changes

• Diabetes Researches

• Primary Care

GCC And UAE Diabetes Devices Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital pharmacies

• Retail Pharmacies

• Diabetes Clinics/ Centers

• Online Pharmacies

• Others

GCC And UAE Diabetes Devices End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Homecare

• Diagnostic centers

GCC And UAE Diabetes Devices Country Outlook (Revenue, USD Million, 2018 - 2030)

• Saudi Arabia

• UAE

• Oman

• Qatar

• Kuwait

• Bahrain

List of Key Players in GCC And UAE Diabetes Devices Market

• Medtronic

• Abbot Laboratories

• Ascensia Diabetes Care Holdings

• Dexcom

• F. Hoffmann- La Roche AG,

• Sanofi

• Novo Nordisk A/S

• Insulet Corporation

• Ypsomed AG

• Eli Lily

• Astra Zeneca